Insulin Glargine
Product Description
Kalbe
-
Country/Region:Indonesia
-
On CPHI since:2018
-
Certificates:3
-
Employees:5000+
Company types
Primary activities
Categories
Specifications
Kalbe
-
Country/Region:Indonesia
-
On CPHI since:2018
-
Certificates:3
-
Employees:5000+
Company types
Primary activities
More Products from Kalbe (2)
-
Product hyfc EPO (long acting)
Efesa, is a long-acting Erythropoietin indicated for CKD-induced anemia in dialysis and non-dialysis patients. Efesa is a hybrid Fc of IgG4 and IgD that provides hinge flexibility and long serum half-life without causing toxicity to target cells. Global Phase 3 trial for non-dialysis indication is currentl... -
Product Nimotuzumab
Nimotuzumab binds with intermediate affinity and high specificity to the extracellular domain of EGFR and blocks the binding of the EGF to its receptor and inhibits tumor cell growth. The molecule induces cell lysis through ADCC mechanism. Nimotuzumab provides vaccinal effect that induce memory T-cell ...
Kalbe resources (1)
-
News Kalbe Establishes Strategic Cooperation with Henlius for Lung Cancer Therapeutic Drug (Serplulimab) in MENA Territories
PT Kalbe Farma Tbk through its subsidiary PT Kalbe Genexine Biologicswith Shangai Henlius Biotech, Inc have entered into an exclusive license agreement for the development and commercialization of serplulimab injection in 12 Middle East and North African countries including Saudi Arabia, the United Arab Emirates, etc.